GlassScriptPhysician profile
Robert P Rabinowitz
NPI 1619983715
$9,880.15
in general payments reported to CMS, 2019-2025
39 companies · $1,872 in 2025
The $1,872 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $932 · 2020: $864 · 2021: $1,086 · 2022: $1,566 · 2023: $1,568 · 2024: $1,992 · 2025: $1,872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,279 · Education: $102 · Consulting Fee: $51.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,278.68 |
| Education | $102.39 |
| Consulting Fee | $51.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,525.85 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $1,500.19 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $565.29 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $545.36 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $452.87 | 2019-2025 | Xolair |
| Csl Behring | $424.52 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Kaleo, INC. | $344.57 | 2019-2024 | Auvi-Q |
| Grifols USA, LLC | $335.05 | 2019-2025 | Xembify |
| Novartis Pharmaceuticals Corporation | $331.63 | 2019-2025 | |
| Optinose US, INC. | $328.13 | 2019-2025 | |
| Amgen INC. | $289.51 | 2021-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $282.50 | 2020-2025 | Takhzyro, Cuvitru, Hyqvia |
| Abbvie INC. | $262.38 | 2022-2023 | |
| Pfizer INC. | $251.05 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $186.60 | 2025 | Neffy |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rabinowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.